Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance

Heron Therapeutics IncTrade
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETFTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.16. The key difference: YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXQDTY
Market Cap
$91.46M
Sector
HealthIncome / Options Overlay
52-Week High
$1.96$46.71
52-Week Low
$0.39$36.57
Enterprise Value
$189.36M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY trades at $39.53 with minimal daily movement (+0.15%). The stock demonstrates consistent dividend distributions with weekly payouts ranging from $0.22 to $0.32 per share throughout 2026. Technical indicators show stable price action while fundamental metrics remain undisclosed in available data. Recent corporate actions focus exclusively on dividend distributions with no significant business developments reported.

The outlook for QDTY appears income-focused given the regular dividend schedule, though fundamental analysis is limited by missing financial ratios. Key risks include dependency on dividend sustainability and potential market volatility. Investment appeal centers on yield generation rather than growth prospects, requiring careful monitoring of underlying financial health.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.

Read more on QDTY